University of Houston optometry researcher provides new hope for injured corneas: Study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I recently learned that there’s a market for branded drug pens. If you have some, hold on to them — they could one day become vintage collectables. Let’s get into the news…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we discuss lots of government maneuvering that impacts biopharma — starting, of course, with the FDA reinstating Vinay Prasad as the director of CBER. We also talk about President Trump’s executive order about federal research grants,…
Good morning everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online meetings and phone calls has predictably returned. But what can you do? The world, such as it is, continues to spin. So time to give it a nudge in…
WASHINGTON — Top drug regulator George Tidmarsh assured Food and Drug Administration staff this week that he and other leaders are trying to bring operations back to normal. “I know that I’m coming in here at a challenging time,” Tidmarsh said at a town hall meeting on Friday with the Center for Drug Evaluation and…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today, we read about the implications of mRNA funding cuts on national security, see layoffs at gene-editing player Tune Therapeutics, and more. Why mRNA funding cuts are a national security issue Health…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. It’s just a mouse study, but intriguing all the same: Lithium may show promise as an Alzheimer’s treatment. Also, Eli Lilly’s oral weight loss pill falls short of GLP-1 stalwarts, and more. The…
Eli Lilly’s investigational obesity pill led to less weight loss in a late-stage trial than the reductions seen with injectable treatments on the market, results that weaken its competitiveness as one of Lilly’s most-anticipated candidates. After 72 weeks, patients taking the highest dose of the therapy, called orforglipron, experienced 11.2% weight loss, when analyzing all…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got a lot of news to get into again today, and if you want to subscribe to read all of it, STAT is running a promo right now that gives you…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I have a huge bag of blueberries that I picked over the weekend. If you have any recipe ideas, send them my way. Onto the biotech news today. Continue to STAT+ to…